SBWire

GlobalData's report "PharmaSphere: Emerging Biotechnologies - Stem Cell Therapy", provides strategic analysis of the global stem cells industry. It discusses key development trends, regulatory requirements in various markets, recent deals activity and industry dynamic trends, as well as describes the operations strategy of these companies. Furthermore, it includes a geographical segmentation of various markets including the EU and US, as well as emerging markets such as China, India, South Korea, and Israel-providing in-depth analysis of these markets' regulatory framework, key domestic players and their stem cell pipelines, and strategic outlook.

Global Markets Direct's, 'Non-Hodgkin Lymphoma - Pipeline Review, H2 2014', provides an overview of the Non-Hodgkin Lymphoma's therapeutic pipeline.

Global Markets Direct's, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2014', provides an overview of the B-Cell Chronic Lymphocytic Leukemia's therapeutic pipeline.

Scott Steiger lives in St. Louis but has seen most of the world. As an engineer for the past 20 years, he’s traveled extensively and prior to that, Steiger was a member of the military service. He’s been to six of the seven continents. Travel is a big part of his life.

Global Markets Direct's, 'N30 Pharmaceuticals - Product Pipeline Review - 2014', provides an overview of the N30 Pharmaceuticals's pharmaceutical research and development focus.

Global Markets Direct's, 'Depression - Pipeline Review, H2 2014', provides an overview of the Depression's therapeutic pipeline.

Global Markets Direct's, 'Alzheimer's Disease - Pipeline Review, H2 2014', provides an overview of the Alzheimer's Disease's therapeutic pipeline.

Global Markets Direct's, 'Urinary Incontinence - Pipeline Review, H2 2014', provides an overview of the Urinary Incontinence's therapeutic pipeline.

GBI Research, the leading business intelligence provider, has released its latest research, "Colorectal Cancer Therapeutics in Asia-Pacific Markets to 2020 - Improved Regional Healthcare Access to Drive Uptake of High-Cost Targeted Therapies", which provides in-depth insights into the indication. It gives an estimation of market size for 2013 along with forecasts until 2020 for the Asia-Pacific (APAC) region, which comprises Australia, China, India and Japan. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of clinical trials including failure rates and pipeline analysis, and analysis of deals relevant to Colorectal Cancer (CRC). The market in the APAC region was worth an estimated $1.9 billion in 2013 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.5% to $1.9 billion in 2020. The use of targeted therapies is expected to increase in the Asia-Pacific (APAC) markets (for the purposes of this report, APAC refers to Australia, China, India and Japan only), as patient access to these more expensive agents improves. The moderate uptake of late-stage pipeline products panitumumab and Xilonix, following their expected approval, is expected to drive additional growth within this market. Others such as ramucirumab, TAS-102, TS-1, MelCancerVac will also contribute. An increasingly aging population and a year-on-year increase in the number of incident cases will provide an additional boost. However, the recent implementation of a price ceiling on essential drugs in India; anticipated pricing restrictions in China; and low access, penetration and price erosion due to generic dominance, especially in India, stand to curtail the APAC CRC market.

Global Markets Direct's, 'Squamous Cell Carcinoma - Pipeline Review, H2 2014', provides an overview of the Squamous Cell Carcinoma's therapeutic pipeline.

The Global Pharmaceutical Market Benchmark Report applies GlobalData's proprietary ranking methodology to compare the competitive positions of 30 leading drug companies on 25 financial metrics. These companies are analyzed based on financial performance, cost-containment, capital structure, and firm utilization to illustrate the different strategies these companies are using to increase value for their shareholders and create a competitive advantage. Throughout the report, GlobalData's Industry Dynamics Team provides expert insight, expanding on each of the metrics discussed.

Global Markets Direct's, 'FibroGen, Inc. - Product Pipeline Review - 2014', provides an overview of the FibroGen, Inc.'s pharmaceutical research and development focus.

HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic.

Global Markets Direct's, 'Sage Therapeutics - Product Pipeline Review - 2014', provides an overview of the Sage Therapeutics's pharmaceutical research and development focus.

Global Markets Direct's, 'Male Hypogonadism - Pipeline Review, H2 2014', provides an overview of the Male Hypogonadism's therapeutic pipeline.

Global Markets Direct's, 'AnaptysBio, Inc. - Product Pipeline Review - 2014', provides an overview of the AnaptysBio, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Aspergillosis - Pipeline Review, H2 2014', provides an overview of the Aspergillosis's therapeutic pipeline.

Global Markets Direct's, 'Peregrine Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Peregrine Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Degenerative Osteoarthritis Global Clinical Trials Review, H2, 2014" provides data on the Degenerative Osteoarthritis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Degenerative Osteoarthritis. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Degenerative Osteoarthritis. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'Dr. Falk Pharma GmbH - Product Pipeline Review - 2014', provides an overview of the Dr. Falk Pharma GmbH's pharmaceutical research and development focus.

Global Markets Direct's, 'Alcoholic Hepatitis - Pipeline Review, H2 2014', provides an overview of the Alcoholic Hepatitis's therapeutic pipeline.

GlobalData's clinical trial report, "Acute Lung Injury Global Clinical Trials Review, H2, 2014" provides data on the Acute Lung Injury clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acute Lung Injury. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Acute Lung Injury. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Global Markets Direct's, 'H3N2 Infection - Pipeline Review, H2 2014', provides an overview of the H3N2 Infection's therapeutic pipeline.

Global Markets Direct's, 'Plantacor, Inc. - Product Pipeline Review - 2014', provides an overview of the Plantacor, Inc.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Pemphigus Global Clinical Trials Review, H2, 2014" provides data on the Pemphigus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Pemphigus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Pemphigus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.